Pasar al contenido principal

Study of cellular and molecular biological pathways driving fibrosis and cancer

RYC-2016-19731

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The multifaceted role of cathepsins in liver disease

  • Ruiz-Blázquez, Paloma
  • Pistorio, Valeria
  • Fernández-Fernández, María
  • Moles, Anna
Proteases are the most abundant enzyme gene family in vertebrates and they execute essential functions in all living organisms. Their main role is to hydrolase the peptide bond within proteins, a process also called proteolysis. Contrary to the conventional paradigm, proteases are not only random catalytic devices, but can perform highly selective and targeted cleavage of specific substrates, finely modulating multiple essential cellular processes. Lysosomal protease cathepsins comprise 3 families of proteases that preferentially act within acidic cellular compartments, but they can also be found in other cellular locations. They can operate alone or as part of signalling cascades and regulatory circuits, playing important roles in apoptosis, extracellular matrix remodelling, hepatic stellate cell activation, autophagy and metastasis, contributing to the initiation, development and progression of liver disease. In this review, we comprehensively summarise current knowledge on the role of lysosomal cathepsins in liver disease, with a particular emphasis on liver fibrosis, non-alcoholic fatty liver disease and hepatocellular carcinoma., AM’s research was supported by a “Research Challenges" R+D+i Project (RTI2018-097475-A-100) and a Ramon y Cajal contract (RYC-2016-19731) awarded by FEDER/Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación. PRB is supported by a FPU PhD studentship (FPU19/05357) funded by Ministerio de Ciencia, Innovación y Universidades. VP held a PhD studentship funded by University of Naples Federico II. MFF salary was supported by JAE Intro fellowship (JAEINT_20_02409) from the Spanish National Research Council (CSIC) and FI AGAUR (2021 FI_B 00249).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Searching for novel cellular targets for MASLD and HCC within the humble lysosomal cathepsins

  • Castillo-Cruz, Alejandro del
  • Fernández-Fernández, María
  • Moles, Anna
Metabolic-associated steatotic liver disease (MASLD) and its pathological version, metabolic dysfunction-associated steatohepatitis (MASH), are becoming the main leading causes of chronic liver disease almost worldwide and are the fastest growing aetiology of hepatocellular carcinoma (HCC), especially in the Western countries. The combination of high incidence and morbidity with limited treatment options for both MASH and HCC highlights an urgent need for the discovery of novel therapeutic candidates to inform drug development. The importance of lysosomes and cathepsins, their most abundant hydrolases, has been overlooked for decades. They were considered organelles only involved in the recycling of macromolecules, with cathepsins simply being their effectors. Contrary to this traditional view, recent findings have shed new light on the lysosome and its enzymes as drivers of essential cellular processes, such as apoptosis and autophagy. Bringing lysosomal activity and the regulation of cathepsins into the spotlight of MASH and HCC research can open new avenues for the development of novel drugs based on targeting cathepsin-driven lysosomal activity and its associated pathological processes. This review comprehensively summarises the current knowledge on the role and contribution of lysosomal cathepsins to MASLD/MASH and HCC progression., This work was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants [PID2021-123652OB-I00] and [RTI2018-097475-A-100] (AM); by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract [RYC-2016-19731] (AM); by Pfizer grant [#77131383] (AM); by CSIC contract [JAEINT_23_01245] (AdCC); and by Ministerio de Universidades, Spain contract [FPU20/01367] (MFF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed